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General anesthetics (GA) are well known for the ability to induce
a state of reversible loss of consciousness and unresponsiveness to
painful stimuli. However, evidence from animal models and clini-
cal studies show that GA exposure may induce behavioral
changes beyond acute effects. Most research and concerns are
focused on changes in cognition and memory. We will look at
effects of GA on behavior that is mediated by the dopaminergic
system. Pharmacological resemblance of GA with drugs of abuse,
and the complexity and importance of dopaminergic systems in
both reward seeking and addictive illnesses make us believe that
it deserves an overview about what is already known and what
matters to us as healthcare workers and specifically as anesthesi-
ologists. A review of available evidence strongly suggests that
there may be a link between the effects of GA on the brain and
substance abuse, partly explained by their influence on the dopa-
minergic system.
Editorial comment: what this article tells us
This review article points out that general anesthesia may induce behavioral changes mediated via
the dopaminergic system, and that some of the same mechanisms may be involved in substance
abuse and reward seeking behavior.
Development of new drugs and technics in
anesthesia was of paramount importance to the
revolution of modern medicine. The pursuit of
the ultimate perioperative homeostatic balance
and increased awareness of safety issues
allowed us to achieve lower levels of morbidity
and mortality as standard of care.1
We have used GA regularly since 1846, but
we have not been able to build a complete the-
ory that unifies both the molecular effects and
the behavioral response of loss and gain of con-
sciousness. The first theory (Meyer–Overton cor-
relation) stated that lipid solubility of GA was
responsible for their anesthetic effects.2 When
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such a generalistic statement failed to explain
how GA work, then the paradigm moved look-
ing for specific molecular targets. The discovery
that GA could interact with the firefly luciferase
enzyme directed research toward proteic tar-
gets.3 Today, we know that GA target neuro-
transmitter receptors in the whole brain,
inducing fast modulation of membrane poten-
tials and neuronal cell firing, as well as slower
modulation of second messenger cascades and
protein synthesis compounds that are responsi-
ble for fast behavioral changes involving arou-
sal, memory, nociception and fear. Additionally,
research has shown us that exposure to GA can
also be responsible for changes that are not so
short-lived.
Reports of temporary cognitive impairment
and long-term neurodevelopmental impairment
in animal models of anesthetic exposure4–6 as
well as clinical reports of decline in cognitive
performance after surgery/anesthesia in
humans7,8 brought an old question to the
spotlight: can GA exposure change the way
we subsequently behave? Now we know that
factors such as surgical procedure together
with individual factors influence patient cogni-
tive outcome9,10 and that exposure to GA
alone has not been proven to be responsible
for cognitive impairment in humans, even in
groups thought to be particularly susceptible
such as children.11 Most research is focused
on cognitive processes, but one particular clin-
ical study, the ISPOCD, reported both higher
risk of prematurely leaving labor market and
of dependence on social transfer payments in
patients who developed postoperative cognitive
dysfunction,12 suggesting that impairment may
extend beyond cognition. Do GA exert a more
subtle influence on us, not necessarily through
a decline in cognition? To answer this particu-
lar questions, we will focus our discussion on
other dimensions of behavior. The molecular
resemblance of GA with drugs of abuse and
the misuse of GA for recreational purposes13
raise concerns about the possible role of GA
as agents that induce changes in motivational
behavior. From all the neurotransmitters that
are targeted by GA, dopamine (DA) is the
most important in motivational and reward
circuitries, with a strong role in conditioning
behaviors. In this review, we will focus on
the possible link between the effects of GA
and drug abuse and how these mechanisms
may help explain some of the potential effects
of GA on the brain.
Understanding the role of dopamine
DA is a catecholaminergic neurotransmitter
present both in the central nervous system and
in several other tissues such as the cardiovascu-
lar and digestive systems. DA is synthesized by
the hydroxylation of the amino acid L-tyrosine
to L-DOPA by tyrosine hydroxylase (TH) which
is further converted to DA by DOPA decarbox-
ylase (or aromatic L-amino acid decarboxylase).
DA is stored in vesicles in the presynaptic ter-
minal by the action of vesicular monoamine
transporter. DA release from dopaminergic neu-
rons into the synaptic cleft is achieved either
through a calcium-dependent exocytic process
similar to other neurotransmitters or through
membrane DA transporter (DAT). Once in the
synaptic cleft, DA binds to and activates DA
receptors (DAR). According to their biochemical
and pharmacological properties, the receptors
can be divided into two subtype families: D1-
like receptor subfamily that includes the D1
and D5 receptors, and the D2-like receptor sub-
family comprising the D2, D3, and D4 recep-
tors.14 The turnover of extracellular DA involves
both degradation by two main enzymes: monoa-
mine oxidase and catechol-O-methyltransferase
and reuptake by DAT, all critical elements in
DA homeostasis.15,16
Dopaminergic neurotransmission plays a criti-
cal role in processes such as learning, memory,
motivation, reward, risk assessment and loco-
motion.17–19 Conditions that challenge DA bal-
ance may impair these functions. In the brain,
we can find higher content in production areas
like pars compacta of the substantia nigra (SN) and
the ventral tegmental area (VTA). From these,
dopaminergic pathways project to the nucleus
accumbens (NAc), the frontal cortex (FC), and
the striatum (Str).
Parkinson’s disease (PD) is a DA-related
pathology in which there is a state of low DA
levels in SN, characterized by several motor
coordination and involuntary movement disor-
ders. PD treatment is based on the use of DA
precursors such as Levodopa (L-DA) and DA
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agonists. Importantly, several reports show that
the prolonged use of these drugs in PD patients
is related to an increase in compulsive gam-
bling/shopping/eating behavior, hypersexuality,
and hyperphagia disorders.20
Changes in brain DA content induce behav-
ioral modifications, but how does this knowl-
edge correlate with the anesthesia field?
Occupational addiction in anesthesia
Substance abuse in health professionals21 is a
known problem. The literature about this sub-
ject shows that occupational hazards do not
translate in an increase in mortality of anesthesi-
ologists compared either with other specialties
or general population22,23; however, there seem
to be an increased risk of substance abuse and
suicide.24,25
The pharmacokinetic of short-acting drugs
such as propofol, remifentanil, and volatile
anesthetics make them virtually impossible to
trace in routine testing, and unless the health
worker is caught consuming or stealing, only
testing all health workers for drugs of abuse
would give us the real picture.
The anesthesiologist faces professional chal-
lenges such as exposure to stressful situations
and work overload that can lead to isolation,
burnout,26 and depression.27 Physicians under
these conditions may, therefore, develop mal-
adaptative strategies that lead to substance
abuse.28 Stress is a known trigger of changes in
brain reward circuits29 that may enhance the
reinforcing properties of drugs. GA have phar-
macological similarities to drugs of abuse:
reports show characteristics of high psychologi-
cal dependence such as relapse, strong cravings,
and continuous auto-administration irrespective
of negative consequences.30 On the top of the
most misused drugs, we can find opioids and
intravenous anesthetics, benzodiazepines, and
lastly volatile anesthetics. There is also specula-
tion that environmental exposure to GA can
induce changes that in a certain way could lead
to the development of addictive traits.31 The fact
that healthcare professionals exposed to stressful
environments also have easy access to drugs
with abuse and misuse potential turn this issue
not an institutional problem but a public health
one.
May general anesthetics be involved in
development of addiction?
Several drugs used during anesthetic procedures
have a direct effect on the dopaminergic system.
The most well-known and studied substances
that induce DA changes and addiction are opi-
oids, but we will focus specifically on GA.
Acute exposure to most GA produces a mixture
of sensations described as feeling drunk, confu-
sion, sedation, and loss of concentration capac-
ity. It can also induce psychadelic-like effects
such as dissociation, hallucinations, and distor-
tions in perception of reality. Volatile anesthet-
ics are chemically similar to solvent agents often
used as recreational drugs and produce similar
behavioral effects.32,33 It is impossible to talk
about anesthetics and DA without recalling the
origins of anesthesia: the first two substances
used as anesthetics, nitrous oxide and ether,
were used recreationally even before being
introduced in medical practice as stated in his-
torical reports describing “laughing gas par-
ties”.34 In human studies,35–38 subanesthetic
doses of sevoflurane, nitrous oxide, propofol,
and ketamine all correlated with liking and
were rated as something the subject “will try
again”; they also produced dose-related rein-
forcement and abuse-related subjective effects.
Ketamine is a well-known club drug, and users
display riskier behavior.39 The effects of GA
exposure in behavior of animal models have
also been studied and correlates with behavioral
changes similar to drugs of abuse such as anxi-
ety and craving. Nitrous oxide is known to
induce anxiolysis in animal models, and the
effect is reversed by the benzodiazepine antago-
nist flumazenil.40 These reports suggest that
exposure to GA can induce addictive behaviors
both in animal models and in humans.
The impact of general anesthetics on brain
dopamine
As above mentioned, GA act in the whole brain:
they modify neuronal system, the release and
reuptake of neurotransmitters, and the way neu-
rons respond to them. The sum of all these
effects represents the behavioral endpoint of GA
action: loss of consciousness, immobility, and
amnesia. DA is believed to contribute to GA
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effects as the amount of dopaminergic activity
influences the amount of GA needed to induce
anesthesia.41 On the other end, the depletion of
brain DA can induce a state of immobility.42
We will now make considerations on the
modulation of DA in brain by different anes-
thetic agents. Most of the data are based in
microdialysis studies where samples of brain
intersticial fluid are sampled during exposure to
GA alone or with DA modulators in transla-
tional research using rodent and primates.
Halotane
Exposure to halothane in high doses increases
extracellular DA levels in Str43–45 and potentiate
the dopaminergic action of other drugs.46,47 The
level of dopaminergic metabolites is also
increased indicating a higher turnover. The use
of lower anesthetic doses fail to increase DA
levels; however, DA metabolites still increase.
So, there seems to be a complex dose-related
response, but there is always some effect. In the
NAc, there is also an increase in DA.48 So evi-
dence show that halothane seems to induce DA
availability in areas that play an important role
in DA driven behavior.
Isoflurane
Isoflurane anesthesia also induces a dose-depen-
dent increase in Str DA49–51 with lower doses
failing to show changes in brain DA but pro-
ducing changes in metabolites.
Nitrous oxide
The use of this volatile NMDA antagonist
induced a slight DA increase in NAc and a
decrease or no effect in Str.52,53
Xenon
Use of xenon failed to change DA levels in NAc.
There are no works regarding other brain
areas.54
Ketamine
In animal models, the NMDA antagonist seems
to have almost no effect in DA levels when used
in low dosages, but higher subanesthetic and
anesthetic dosages increase DA in Str, NAc and
FC.55–58 This effect is also seen in human
in vivo imaging studies that report an increase
in striatal DA release after an acute challenge
with ketamine.59 But when the exposure is
repeated, there is a reduction in FC dopaminer-
gic function with impairment in working mem-
ory and executive functions.60
Pentobarbital
Pentobarbital induces decreases DA in the NAc,
producing a state of ataxia in rodents. It also
inhibits the effect of L-DOPA in extracellular
DA increase.50 Like other GAs, when given in
lower doses does not change DA levels.58
Propofol
Propofol at lower subanesthetic dosages
decreases DA NAc content while more clinically
relevant higher subanesthetic and anesthetic
dosages of propofol increase NAc DA levels.61
Propofol also has the ability to induce expres-
sion of DeltaFosB in NAc, a protein whose
expression is also increased by drugs of abuse.62
Additionally, propofol exposure decreases DA
levels in Str and in FC.63
Measurements of dopaminergic activity either
in DA production, degradation, and reuptake
can be used to assess dopaminergic pathways.
DA is degraded into 3,4-Dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA). In
rodents, DOPAC is the major metabolite and
DOPAC accumulation provides an indicator of
dopaminergic neurons activity, while the
DOPAC:DA ratio is an indication of DA turn-
over. In Str, DA metabolite levels are increased
by halothane, isoflurane, sevoflurane, and prop-
ofol exposure.44–46,64 In the NAc, they are
increased after exposure to isoflurane,65 sevoflu-
rane, and propofol. In addition, DAT seems to
be inhibited by most GAs. In fact, studies show
that halothane, isoflurane, propofol, ketamine,
ethomidate, and thiopental inhibit specific
synaptosomal uptake of DA in a concentration-
dependent manner in rat brain.41,66,67 The over-
all effect of exposure to GA is a dose-dependent
increase in DA and its metabolites during acute
exposure.
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What are the implications of changed DA levels
induced by GA?
We will now focus the effect of GA in brain
areas relevant to DA-driven behavior. Striatal
influence of GA seems to be “agent” and “dose-
specific”, but there is no doubt that GA have
an impact on Str DA release. The Str serves as
the entry point for cortical and thalamic inputs
into basal ganglia circuitry. The release of DA
in Str during reward learning tasks is known
to be an important modulator of acquisition of
habit or goal-directed tasks. Disorders that
affect DA such as PD, Huntington’s disease,
and substance abuse produce impairments in
these processes. Exposure to GA specifically
halothane, isoflurane, and ketamine have the
potential to impair those functions through
changes in Str DA.43–47,49–51,55
The NAc is believed to participate in many
functions that have been shown to be important
in reward learning tasks.68 Most drugs of abuse
are known to produce an increase in DA levels
at the NAc, in a manner similar to propofol, ke-
tamine, and halothane.48,52,57
Dopaminergic activity in the prefrontal cortex
(PFC) plays an important role in cognitive func-
tions. DA depletion in PFC impairs working
memory performance tasks in primates69,70 and
the use of DA agonists improves performance in
animals with poor working memory.71,72 Both
human and animal studies suggest that repeated
exposure to noncompetitive NMDA antagonists
reduces PFC dopaminergic function with
impairment in working memory and executive
function.73,74 We can speculate that while acute
exposure to GA with NMDA antagonist activity
induces increase in PFC DA, continuous expo-
sure is prone to decrease PFC DA and impair
working memory and executive function perfor-
mance which is the pattern found in chronic
users. Chronic exposure to GA, such as repeated
anesthetic procedures, theoretically can induce
the same changes. Such as stated earlier, there
are concerns of a similar mechanism responsible
for development of addiction in susceptible
individuals subjected to environmental expo-
sure.
To summarize, increase in DA metabolites
suggests that most GA induce higher DA levels
and turnover in several brain regions, especially
in the Str and in the NAc. Activation of these
particular areas is a hallmark pattern of several
drugs that induce addiction and impair DA dri-
ven behavior.
Conclusion
Review of the literature suggests that general
anesthesia modulates the dopaminergic path-
ways. Behavioral data both in human and ani-
mal models support the possible development
of an addictive trait in subjects exposed to GA.
Some of the molecular features of drugs of abuse
concerning DA are also found in GA such as DA
release and availability in areas such as NAc
and Str. It is likely that all behavior functions
that rely on dopaminergic transmission can be
potentially impaired after GA exposure.
Changes in reward system and memory forma-
tion potentially may impair cognitive abilities
such as reasoning, language comprehension,
planning, and spatial processing. Several clini-
cal trials show that surgery and anesthesia may
cause “postoperative cognitive dysfunction” and
changes in dopaminergic brain systems may
contribute to this phenomenon. However, we
still do not know how much it impacts on our
behavior. The potential to play with reward
mechanism, decision-making processes and cog-
nitive performance impose a need for judicious
use of GA. Further research is needed to answer
all these questions and provide both even better
standard of care to our patients and less occupa-
tional hazards to healthcare workers.
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